Next earnings date: 11 Aug 2025
PharmaCyte Biotech, Inc. – NASDAQ:PMCB
PharmaCyte Biotech stock price today
PharmaCyte Biotech stock price monthly change
PharmaCyte Biotech stock price quarterly change
PharmaCyte Biotech stock price yearly change
PharmaCyte Biotech key metrics
Market Cap | 11.49M |
Enterprise value | N/A |
P/E | -10.96 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.72 |
PEG ratio | -0.12 |
EPS | -0.15 |
Revenue | N/A |
EBITDA | -4.18M |
Income | -1.97M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePharmaCyte Biotech stock price history
PharmaCyte Biotech stock forecast
PharmaCyte Biotech financial statements
| Apr 2022 | 0 | -1.25M | |
|---|---|---|---|
| Jan 2023 | 0 | 24.71K | |
| Apr 2023 | 0 | -126.33K | |
| Jan 2024 | 0 | -619.53K |
| Oct 2022 | 82348703 | 1.31M | 1.59% |
|---|---|---|---|
| Jan 2023 | 77950534 | 827.83K | 1.06% |
| Apr 2023 | 73276925 | 586.58K | 0.8% |
| Jan 2024 | 71359398 | 22.46M | 31.48% |
| Apr 2022 | -1.19M | 0 | -50.80K |
|---|---|---|---|
| Jan 2023 | -541.70K | 0 | -3.77M |
| Apr 2023 | -288.38K | 0 | -4.30M |
| Jan 2024 | -177.10K | -5M | -7.03M |
PharmaCyte Biotech alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 2 |
| Oct 2023 | 2 |
| Nov 2023 | 2 |
| Dec 2023 | 2 |
| Jan 2024 | 2 |
| Feb 2024 | 2 |
| Mar 2024 | 2 |
| Apr 2024 | 2 |
| May 2024 | 2 |
| Jun 2024 | 2 |
| Jul 2024 | 2 |
PharmaCyte Biotech other data
| Insider | Compensation |
|---|---|
Mr. Kenneth L. Waggoner Esq. (1948) Chairman, Chief Executive Officer, Pres, Gen. Counsel & Sec. | $433,330 |
Mr. Carlos A. Trujillo CPA, CPA (1958) Chief Financial Officer & Director | $300,000 |
Dr. Gerald W. Crabtree Ph.D. (1941) Chief Scientific Officer & Director | $94,330 |
Tuesday, 21 May 2024 | ||
| PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease | businesswire.com | |
| MyMD Pharmaceuticals Secures Strategic Investments | businesswire.com |
-
What's the price of PharmaCyte Biotech stock today?
One share of PharmaCyte Biotech stock can currently be purchased for approximately $1.03.
-
When is PharmaCyte Biotech's next earnings date?
PharmaCyte Biotech, Inc. is estimated to report earnings on Monday, 11 Aug 2025.
-
Does PharmaCyte Biotech pay dividends?
No, PharmaCyte Biotech does not pay dividends.
-
How much money does PharmaCyte Biotech make?
PharmaCyte Biotech has a market capitalization of 11.49M.
-
What is PharmaCyte Biotech's stock symbol?
PharmaCyte Biotech, Inc. is traded on the NASDAQ under the ticker symbol "PMCB".
-
What is PharmaCyte Biotech's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of PharmaCyte Biotech?
Shares of PharmaCyte Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are PharmaCyte Biotech's key executives?
PharmaCyte Biotech's management team includes the following people:
- Mr. Kenneth L. Waggoner Esq. Chairman, Chief Executive Officer, Pres, Gen. Counsel & Sec.(age: 77, pay: $433,330)
- Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer & Director(age: 67, pay: $300,000)
- Dr. Gerald W. Crabtree Ph.D. Chief Scientific Officer & Director(age: 84, pay: $94,330)
-
How many employees does PharmaCyte Biotech have?
As Jul 2024, PharmaCyte Biotech employs 2 workers.
-
When PharmaCyte Biotech went public?
PharmaCyte Biotech, Inc. is publicly traded company for more then 12 years since IPO on 2 Jan 2013.
-
What is PharmaCyte Biotech's official website?
The official website for PharmaCyte Biotech is pharmacyte.com.
-
Where are PharmaCyte Biotech's headquarters?
PharmaCyte Biotech is headquartered at 3960 Howard Hughes Parkway, Las Vegas, NV.
-
How can i contact PharmaCyte Biotech?
PharmaCyte Biotech's mailing address is 3960 Howard Hughes Parkway, Las Vegas, NV and company can be reached via phone at +91 75952850.
PharmaCyte Biotech company profile:
PharmaCyte Biotech, Inc.
pharmacyte.comNASDAQ
2
Biotechnology
Healthcare
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Las Vegas, NV 89169
CIK: 0001157075
ISIN: US71715X2036
CUSIP: 71715X203
